Browsing Tag
Radiopharm Theranostics
3 posts
Radiopharm Theranostics begins third-cohort enrolment in Phase 1 ¹⁷⁷Lu-RAD204 trial targeting PD-L1 tumours
Find out how Radiopharm Theranostics is advancing ¹⁷⁷Lu-RAD204 in PD-L1-positive tumours as it begins third-cohort enrolment in its Phase 1 trial.
Radiopharm Theranostics (ASX: RAD) crashes 21.6% despite A$40m capital raise and clinical milestones
Radiopharm Theranostics shares fall 21.6% after A$40m raise, but strong clinical updates and Lantheus support point to long-term upside. Read the full investor breakdown.
Radiopharm Theranostics’ 68Ga-RAD 301 shows promise in pancreatic cancer imaging
Radiopharm Theranostics, a clinical-stage biopharmaceutical company, has announced compelling results from a study examining the effectiveness of 68Ga-Trivehexin…